Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ModCAR Her2
- Development stage
- Preclinical
- Lead developer
- Hauul Bio
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
ModCAR Her2 is a non-viral modular chimeric antigen receptor (CAR) cell therapy being developed by Hauul Bio for the treatment of solid cancers. The therapy utilizes Hauul Bio's proprietary ModCAR platform, which employs a recombinant scFv-fusion protein to recognize and target HER2-positive tumor cells. Unlike conventional CAR-T therapies that rely on viral vectors for gene transduction, the ModCAR platform introduces the CAR system into immune cells non-virally, aiming to simplify the manufacturing process, reduce costs, and improve safety.
- Other names
- HER2-targeting ModCARHER-2-targeting ModCARHER 2-targeting ModCARModCAR HER2
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on ModCAR Her2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ModCAR Her2.